NEMA HEALTH develops Onconeovac, a personalized immunotherapy that combines tumor neoantigens with patented DIF immunostimulatory peptides. The program is currently focused on advanced/metastatic melanoma and aims to be used in combination with other therapies; preclinical animal studies showed tumor prevention and growth reduction comparable to anti‑PD1 and up to fourfold greater reduction when combined with anti‑PD1. The company intends to accelerate preclinical development and investigate applications in other solid tumors and in veterinary oncology. NEMA HEALTH originated as a spin-off from VHIR and the University of Lleida through The Collider program. The recent seed raise and NEOTEC grant are being used to scale peptide manufacturing capacity via BCN Peptides and to professionalize the company’s structure, including the formation of a new board of directors.

Total raised

$1M

Funding rounds

2

Latest round

Grant

Latest activity

Mar 2026